Tablet strength

Tablet Formulations (Immediate Release). Two papers in the mid-1990s reported the earliest studies on immediate release tablets. In the first, tablet formulations of hydrochlorothiazide [33] were modeled in an attempt to maximize tablet strength and select the best lubricant. In the other, a tablet formulation of caffeine was modeled [34] to relate both formulation and processing variables with granule and tablet properties.

It is also important to appreciate that the behavior on decompression can markedly affect the characteristics of the finished tablets, because the structure must be strong enough to accommodate the recovery- and ejection-induced stresses. Indeed, tablet strength is a direct function of the number of surviving bonds in the finished tablet. In addition, ability to monitor... 

Septra DS is given as ibid, 14 such tablets are needed for seven days, brand drug should be dispensed, tablet strength for DS should be 800/ 160, and the DEA is wrong... 

Starting dose for patients inadequately controlled on metformin monotherapy -Based on the usual starting dose of pioglitazone (15 to 30 mg daily), pioglitazone/metformin may be initiated at either the 15 mg/500 mg or 15 mg/850 mg tablet strength once or twice daily, and gradually titrated after assessing adequacy of therapeutic response. 

Oxycodone CR tablets are not intended for use as an as-needed analgesic. Oxycodone 80 and 160 mg CR tablets are for use in opioid-tolerant patients only. These tablet strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids. 

With either method, dose and dosing interval is then adjusted as needed. The 15 mg ER tablet should be used for initial conversion for patient s total daily requirement is expected to be less than 60 mg. Morphine ER tablets of 30 mg strength are recommended for patients with a daily morphine requirement of 60 to 120 mg. When the total daily dose is expected to be greater than 120 mg, the appropriate tablet strength should be employed. 

Conversion from parenteral morphine or other opioids (parenteral or oral) to CR/ER/SR doseforms- Exercise particular care in the conversion process. Because of uncertainty about, and intersubject variation in, relative estimates of opioid potency and cross-tolerance, initial dosing regimens should be conservative that is, an underestimation of the 24-hour oral morphine requirement is preferred to an overestimate. To this end, estimate initial individual doses conservatively. In patients whose daily morphine requirements are expected to be 120 mg/day or less, the 30 mg tablet strength is recommended for the initial titration period. Once a stable dose regimen is reached, the patient can be converted to the 60 or 100 mg tablet strength, or appropriate combination of tablet strengths, if desired. Conversion from CR/ER/SR oral morphine to parenteral opioids - It is best to assume that the parenteral-to-oral potency is high. For example, to estimate the required 24-hour dose of morphine for IM use, one could employ a conversion of 1 mg morphine IM for every 6 mg of morphine... 

Round down to a dose that is appropriate for the tablet strengths available. 

CR tablets, 80 and 160 mg, are for use only in opioid-tolerant patients requiring daily oxycodone equivalent dosages of at least 160 mg for the 80 mg tablet and at least 320 mg for the 160 mg tablet. Take care in the prescribing of these tablet strengths. Instruct patients against use by individuals other than the patient for whom it was prescribed, as such inappropriate use may have severe medical consequences, including death. 

Oral solution - The oral solution can be given on a mg-per-mg basis in place of the 5,10,15, or 20 mg tablet strengths. Patients receiving 30 mg tablets should receive 25 mg of the solution. 

Force measurements made without displacement values are still useful in identifying the dependency of tablet hardness (and other associated characteristics) on compaction force, and also the effect of the tablet press compaction speed on tablet strength (influence of dwell time/effective... 

As shown in Table 7, compacts of all three mannitol products displayed relatively low TS at the test SF, particularly the powdered and 2080 grades. Only Mannogem EZ formed tablets with moderate strength. Low TS is perhaps one of the main disadvantages of these mannitol grades, because it contributes relatively little to tablet strength and robustness. 

As discussed later, compression and densification during compaction can be followed by monitoring and measuring density and porosity. The monitoring of the consolidation, i.e., the bonding process to create the tablet strength, is more difficult. It should be clear, and can be emphasized again, that the important parameters in this operation are the physicochemical properties of the powder and the equipment used to perform this operation. 

Tablet strengths. Orders specifying both strength and number of tablets are confusing when more than one tablet strength exists. For example, Metoprolol... 

David ST, Augsburger LL. 1977. Plastic flow during compression of directly compressible fillers and its effect on tablet strength. J. Pharm. Sci. 66(2) 155-159. 

During development of Compound B, several low-dose tablet formulations were investigated in clinical studies, including 0.05, 0.1, 0.25, and 0.4 mg tablet strengths. With these low-dose tablets, dissolution testing in 500 mL yielded low sample... 

Table 13.12 Effects of punch design and compression force on tablet strength (MPa)...

Adolfsson, A., and Nystrom, C. (1996), Tablet strength, porosity, elasticity and solid state structure of tablets compressed at high loads, Int. I. Pharm., 132, 95-106. 

---